SINO BIOPHARMACEUTICAL, SINO BIOPHARMACEUTICAL, Ucb ADR, Ucb SA, and Jazz Pharmaceuticals plc" name="Description" /> SINO BIOPHARMACEUTICAL, SINO BIOPHARMACEUTICAL, Ucb ADR, Ucb SA, and Jazz Pharmaceuticals plc" /> SINO BIOPHARMACEUTICAL, SINO BIOPHARMACEUTICAL, Ucb ADR, Ucb SA, and Jazz Pharmaceuticals plc" />

The Top 5 Biotech stocks to own in September 2019

Today I will analyze 5 Biotech isntruments to have in your portfolio in September 2019. I will break down the following equities: SINO BIOPHARMACEUTICAL, SINO BIOPHARMACEUTICAL, Ucb ADR, Ucb SA, and Jazz Pharmaceuticals plc
Published over a year ago
View all stories for Macroaxis | View All Stories
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Michael Smolkin

This list of potential positions covers Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services in USA. Please note, we provide buy hold or sell recommendation only in the context of selected investment horizon assuming investor has average attitude towards taking risk. Please also consider using Portfolio Positions Ratings and Equity Ratings tools to further calibrate your research.
Story appears to be empty

Sino Biopharmaceutical (SBHMY)

The company has return on total asset (ROA) of 0.0451 % which means that it generated a profit of $0.0451 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2908 %, meaning that it generated $0.2908 on every $100 dollars invested by stockholders. Sino Biopharmaceutica's management efficiency ratios could be used to measure how well Sino Biopharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities. The entity currently falls under 'Large-Cap' category with a current market capitalization of 10.88 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Sino Biopharmaceutica's market, we take the total number of its shares issued and multiply it by Sino Biopharmaceutica's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the company appears to be overvalued. Sino Biopharmaceutical has a current Real Value of $6.96 per share. The regular price of the company is $8.2. Our model measures the value of Sino Biopharmaceutical from inspecting the company fundamentals such as Return On Equity of 0.29, shares outstanding of 940.69 M, and Operating Margin of 0.16 % as well as reviewing its technical indicators and probability of bankruptcy. In general, most investors recommend acquiring undervalued stocks and dropping overvalued stocks since, at some point, asset prices and their ongoing real values will draw towards each other.

UCB SA ADR (UCBJY)

The company has return on total asset (ROA) of 0.0468 % which means that it generated a profit of $0.0468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1069 %, meaning that it generated $0.1069 on every $100 dollars invested by stockholders. UCB SA's management efficiency ratios could be used to measure how well UCB SA manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Large-Cap' category with a current market capitalization of 15.86 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate UCB SA's market, we take the total number of its shares issued and multiply it by UCB SA's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

UCB SA (UCBJF)

The company has return on total asset (ROA) of 0.0468 % which means that it generated a profit of $0.0468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1069 %, meaning that it generated $0.1069 on every $100 dollars invested by stockholders. UCB SA's management efficiency ratios could be used to measure how well UCB SA manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Large-Cap' category with a current market capitalization of 15.88 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate UCB SA's market, we take the total number of its shares issued and multiply it by UCB SA's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the entity appears to be overvalued. UCB SA owns a latest Real Value of $111.7 per share. The recent price of the entity is $119.9. Our model measures the value of UCB SA from evaluating the entity fundamentals such as Return On Asset of 0.0468, shares owned by insiders of 38.03 %, and Profit Margin of 0.15 % as well as inspecting its technical indicators and probability of bankruptcy. In general, most investors recommend locking in undervalued equities and disposing overvalued equities since, in the future, asset prices and their ongoing real values will merge together.

Jazz Pharmaceuticals PLC (JAZZ)

The company has return on total asset (ROA) of 0.0456 % which means that it generated a profit of $0.0456 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1216 %, meaning that it created $0.1216 on every $100 dollars invested by stockholders. Jazz Pharmaceuticals' management efficiency ratios could be used to measure how well Jazz Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Jazz Pharmaceuticals' Return On Assets are fairly stable compared to the past year. Return On Equity is likely to rise to 0.22 in 2024, whereas Return On Capital Employed is likely to drop 0.06 in 2024. At this time, Jazz Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 8.5 B in 2024, despite the fact that Net Tangible Assets are likely to grow to (3.7 B). The firm currently falls under 'Mid-Cap' category with a current market capitalization of 7.35 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Jazz Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Jazz Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Short Long Term Debt Total

6.09 Billion

At this time, Jazz Pharmaceuticals' Short and Long Term Debt Total is fairly stable compared to the past year.

Current Biotech Recommendations


How important is Macroaxis's Liquidity

Macroaxis financial leverage refers to using borrowed capital as a funding source to finance Macroaxis ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Macroaxis financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Macroaxis' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Macroaxis' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Macroaxis's total debt and its cash.
Story appears to be empty

Sino Biopharmaceutical (SBHMY)

The company has return on total asset (ROA) of 0.0451 % which means that it generated a profit of $0.0451 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2908 %, meaning that it generated $0.2908 on every $100 dollars invested by stockholders. Sino Biopharmaceutica's management efficiency ratios could be used to measure how well Sino Biopharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities. The entity currently falls under 'Large-Cap' category with a current market capitalization of 10.88 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Sino Biopharmaceutica's market, we take the total number of its shares issued and multiply it by Sino Biopharmaceutica's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the company appears to be overvalued. Sino Biopharmaceutical has a current Real Value of $6.96 per share. The regular price of the company is $8.2. Our model measures the value of Sino Biopharmaceutical from inspecting the company fundamentals such as Return On Equity of 0.29, shares outstanding of 940.69 M, and Operating Margin of 0.16 % as well as reviewing its technical indicators and probability of bankruptcy. In general, most investors recommend acquiring undervalued stocks and dropping overvalued stocks since, at some point, asset prices and their ongoing real values will draw towards each other.

UCB SA ADR (UCBJY)

The company has return on total asset (ROA) of 0.0468 % which means that it generated a profit of $0.0468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1069 %, meaning that it generated $0.1069 on every $100 dollars invested by stockholders. UCB SA's management efficiency ratios could be used to measure how well UCB SA manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Large-Cap' category with a current market capitalization of 15.86 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate UCB SA's market, we take the total number of its shares issued and multiply it by UCB SA's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

UCB SA (UCBJF)

The company has return on total asset (ROA) of 0.0468 % which means that it generated a profit of $0.0468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1069 %, meaning that it generated $0.1069 on every $100 dollars invested by stockholders. UCB SA's management efficiency ratios could be used to measure how well UCB SA manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Large-Cap' category with a current market capitalization of 15.88 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate UCB SA's market, we take the total number of its shares issued and multiply it by UCB SA's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the entity appears to be overvalued. UCB SA owns a latest Real Value of $111.7 per share. The recent price of the entity is $119.9. Our model measures the value of UCB SA from evaluating the entity fundamentals such as Return On Asset of 0.0468, shares owned by insiders of 38.03 %, and Profit Margin of 0.15 % as well as inspecting its technical indicators and probability of bankruptcy. In general, most investors recommend locking in undervalued equities and disposing overvalued equities since, in the future, asset prices and their ongoing real values will merge together.

Jazz Pharmaceuticals PLC (JAZZ)

The company has return on total asset (ROA) of 0.0456 % which means that it generated a profit of $0.0456 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1216 %, meaning that it created $0.1216 on every $100 dollars invested by stockholders. Jazz Pharmaceuticals' management efficiency ratios could be used to measure how well Jazz Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Jazz Pharmaceuticals' Return On Assets are fairly stable compared to the past year. Return On Equity is likely to rise to 0.22 in 2024, whereas Return On Capital Employed is likely to drop 0.06 in 2024. At this time, Jazz Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 8.5 B in 2024, despite the fact that Net Tangible Assets are likely to grow to (3.7 B). The firm currently falls under 'Mid-Cap' category with a current market capitalization of 7.35 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Jazz Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Jazz Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Short Long Term Debt Total

6.09 Billion

At this time, Jazz Pharmaceuticals' Short and Long Term Debt Total is fairly stable compared to the past year.

Current Biotech Recommendations

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Did you try this?

Run Alpha Finder Now

   

Alpha Finder

Use alpha and beta coefficients to find investment opportunities after accounting for the risk
All  Next Launch Module
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any private could be tightly coupled with the direction of predictive economic indicators such as signals in persons.
You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Other Consideration for investing

Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Equity Valuation
Check real value of public entities based on technical and fundamental data